• Alfresa Holdings' Integrated Report 2026 details a shift beyond traditional pharmaceutical wholesaling toward integrated supply chain services.
• Ethical pharmaceutical wholesaling outpaced market growth in fiscal 2025, strengthening its leading market position.
• PATH-Solution launched in January 2026 to support overseas drugmakers entering Japan; initial inquiries have already translated into contracts.
• Ark Medical Solutions became a consolidated subsidiary effective April 1, 2026, expanding clinical research and post-marketing surveillance capabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alfresa Holdings Corporation published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.